

# Cresulip<sup>®</sup>

*Rosuvastatin Calcium*



**The Lipid Balance**




# Cresulip<sup>®</sup>

Rosuvastatin Calcium

## High Tolerability Profile

Percentage of patients with an adverse event leading to withdrawal



Adapted from Brewer HB et al. Am J Cardiol 2003;92(Suppl):23K-29K


- Rosuvastatin is well tolerated<sup>5</sup>
- Adverse events were mild and transient with low withdrawal rate<sup>5</sup>

# Cresulip<sup>®</sup>


Rosuvastatin Calcium

## Powerful Impact on Key Lipid Parameters

- Rosuvastatin demonstrates highly effective reductions on LDL-C<sup>1</sup>




- Rosuvastatin produces a significant increase in HDL-C<sup>1</sup>




- This increase in HDL-C is maintained across its dosage range<sup>1</sup>

## Remarked Influence on the Progression of Atherosclerosis

- **Rosuvastatin** significantly lowers progression of atherosclerosis compared to placebo in patients at low risk for CAD<sup>2</sup>




- Long term treatment with **Rosuvastatin** results in a significant regression in Coronary Atheroma Burden in patients with established coronary disease<sup>3</sup>



- Regression occurred in almost 4 out of 5 patients<sup>3</sup>

## Documented Reductions in CV Mortality and Morbidity

- **Rosuvastatin** significantly reduces the incidence of major cardiovascular events\* in patients with low to normal LDL-C but at increased risk for CAD<sup>4</sup>



- The number needed to treat to prevent the occurrence of one event\* is 25<sup>4</sup>

\*Events including: nonfatal myocardial infarction, nonfatal stroke, arterial revascularization, hospitalization for unstable angina or confirmed death from cardiovascular causes

# Cresulip<sup>®</sup>

*Rosuvastatin Calcium*

- Produces powerful impact on key lipid parameters at low dose and across the dosage range
- Achieves remarked influence on the progression of atherosclerosis
- Shows remarked regression in Coronary Atheroma Burden in patients with established coronary disease
- Documented reductions in cardiovascular mortality and morbidity
- Generally well tolerated

## Help Achieve The Lipid Balance With Cresulip<sup>®</sup>

#### References:

(1) Jones PH et al. Am J Cardiol 2003;92:152–160. (2) Crouse JR III, et al. JAMA. 2007. 297(12):1344–1345. (3) Nissen S et al. JAMA 2006; 295 (13):1556–1565. (4) Ridker et al. N Engl J Med 2008, volume 359, Number 21. (5) Brewer HB et al. Am J Cardiol 2003;92(-Suppl):23K–29K.

Before prescribing please consult physicians' circular.

<sup>®</sup> Registered trade name

Cresulip<sup>®</sup> manufactured by   
State of the art manufacturing facility  
Certified European GMP  
ISO Certified



**CE GMP**

Benta Pharma Industries - Dbayeh, Lebanon